Though President Trump vowed to "eliminate the middlemen," pharmacy benefit managers (PBMs) saw the White House’s drug pricing blueprint as an endorsement of at least some of the private sector policy agenda.
The share specialty drugs have of total U.S. pharmaceutical sales nears 50% as President Trump prepares to unveil proposals to curtail drug prices.